The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index; 16 of the 147 sources its claims cite were checked for support.
The biological and clinical significance of emerging SARS-CoV-2 variants
Open accessAbstract
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel spike protein mutations that are influencing the epidemiological and clinical aspects of the COVID-19 pandemic. These variants can increase rates of virus transmission and/or increase the risk of reinfection and reduce the protection afforded by neutralizing monoclonal antibodies and vaccination. These variants can therefore enable SARS-CoV-2 to continue its spread in the face of rising population immunity while maintaining or increasing its replication fitness. The identification of four rapidly expanding virus lineages since December 2020, designated variants of concern, has ushered in a new stage of the pandemic. The four variants of concern, the Alpha variant (originally identified in the UK), the Beta variant (originally identified in South Africa), the Gamma variant (originally identified in Brazil) and the Delta variant (originally identified in India), share several mutations with one another as well as with an increasing number of other recently identified SARS-CoV-2 variants. Collectively, these SARS-CoV-2 variants complicate the COVID-19 research agenda and necessitate additional avenues of laboratory, epidemiological and clinical research. In this Review, the authors describe our latest understanding of the emergence and properties of SARS-CoV-2 genetic variants, particularly those designated as WHO (World Health Organization) ‘variants of concern’. They focus on the consequences of these variants for antibody-mediated virus neutralization, with important implications for reinfection risk and for vaccine effectiveness.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review synthesizes SARS-CoV-2 evolution, spike structure and the biological/clinical significance of the four WHO variants of concern as of June 2021: Alpha, Beta, Gamma and Delta. It shows that recurrent spike mutations increase transmissibility and immune evasion, reducing neutralization by monoclonal antibodies and vaccinee plasma, and calls for integrated genomic, neutralization and vaccine-efficacy surveillance.
Key findings
- Four VOCs emerged independently: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2). Alpha was estimated to be ~50% more transmissible than prior UK variants and associated with an estimated 50% increased mortality; Beta was estimated to be 50% more transmissible than preceding lineages; Gamma was estimated to cause 3–4 times higher virus levels and 1.1-fold to 1.8-fold higher mortality; Delta spread to 54 countries and replaced Alpha in the UK and USA.
- Neutralization escape varied by variant. Beta showed 3-fold to 10-fold reduced susceptibility to 46% and >10-fold reduced susceptibility to 22% of convalescent plasma samples; mRNA vaccinee plasma showed 45% with 3-fold to 10-fold and 30% with >10-fold reduced Beta neutralization. Delta showed 3-fold to 10-fold reduced susceptibility to 45% and >10-fold to 5% of convalescent plasma samples, while ~15% of BNT162b vaccinee plasma had 3-fold to 10-fold reduced Delta neutralization. Alpha was rarely associated with reduced convalescent plasma susceptibility but showed 3-fold to 10-fold reduced susceptibility to ~15% of mRNA vaccinee plasma samples.
- Vaccine efficacy against VOCs was reduced in several studies: BNT162b retained >90% efficacy against Alpha in Israel and Qatar; Beta efficacy was 72% in a Qatar cohort and 75% in a test-negative case-control study; Delta efficacy was ~85% for BNT162b and ~60% for AZD1222 in UK case-control studies. In trials, AZD1222 efficacy against Beta was 10% in South Africa, and NVX-CoV2373 efficacy was 49% against Beta and 86.3% against Alpha versus 96.4% against non-Alpha variants.
- Key mutations include D614G, which rose to near 100% global prevalence by June 2020; N501Y, which increases ACE2 affinity; E484K, which reduces susceptibility to several monoclonal antibodies and plasma; and non-spike mutations that antagonize innate immunity, with Alpha and Beta showing mean 112-fold and 8-fold reduced susceptibility to type I interferons, respectively, compared with an early pandemic virus.
Methods
- Narrative review creating a framework for SARS-CoV-2 variants by describing evolution, spike protein structure/function, laboratory characterization methods, biological and epidemiological properties of VOCs/VOIs, and required research responses; data summarized as of June 2021.
- Synthesizes genomic surveillance data from more than two million partially or fully sequenced virus isolates, in vitro selection and neutralization experiments using pseudotyped viruses, VSV-based chimeric viruses, full-length recombinant SARS-CoV-2 and cultured isolates, deep mutational scanning, and vaccine efficacy trials, test-negative case-control studies and cohort studies.
- Neutralization results were pooled in the Stanford University Coronavirus Antiviral & Resistance Database and summarized as <3-fold, 3–10-fold and >10-fold reductions compared with control viruses.
Limitations
- The paper states that as of June 2021 it is uncertain whether current lineage-based variant classification will be sustainable, and that classifying variants by component mutations may become challenging if recurrent mutations increase.
- The paper notes unresolved questions, including whether neutralizing antibodies are the most important protective mechanism versus memory B cells, Fc-effector functions and T cell immunity, and whether updated immunogens can broaden responses in animal models more predictive of humans.
- Evident from the text: this is a synthesis as of June 2021, so later variants and data are not included; neutralization estimates pool results across pseudotyped, chimeric and infectious virus assays, and some distributions are approximate because they include results reported only as aggregate mean fold reductions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
70 Not checked yet · 10 Own interpretation · 7 Partly supported · 3 No basis given · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, in three other studies, the median reduction in neutralizing activity was between onefold and threefold 102,214,215 .”
What the sources say
- Partly supportedcites [102] Supasa, P. et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201–2211 (2021). sourceExperimental — accuracy not yet measured
The Results section ('Neutralization activity of convalescent plasma and vaccine sera'; page not provided) reports a 2.9-fold reduction for convalescent plasma and 2.1- and 2.5-fold reductions for AstraZeneca vaccine sera, all within the claimed range. These are geometric means, not medians, and the reported Pfizer vaccine-serum reduction is 3.3-fold, outside that range. This source cannot establish the results of the other two cited studies. (LLM, conf=0.85)
- Supportedcites [214] Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021). source
In “Sensitivity of Delta to convalescent sera” (page unavailable), the paper reports median neutralization titres and says Delta titres were fourfold lower than Alpha titres and sixfold lower than D614G titres. Those comparisons imply an approximately 1.5-fold reduction for Alpha relative to D614G, within the claimed onefold-to-threefold range. This paper is one of the three studies cited; it need not itself report the other two. (LLM, conf=0.84)
- Not checked yetcites [215] Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough. Preprint at Research Square https://www.researchsquare.com/article/rs-637724/v1 (2021).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of plasma samples obtained from persons receiving one of the mRNA vaccines, 45% had 3-fold to 10-fold and 30% had >10-fold reduced Beta variant neutralizing activity 97,104,117,121,151,204,208,209,222,223 (fIg.5).”
What the sources say
- Not checked yetcites [97] Chen, X. et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab646 (2021). This paper presents a systematic review and meta-analysis of in vitro neutralization studies of SARS-CoV-2 variants by convalescent and vaccinee plasma. source
- Partly supportedcites [104] Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2348–2361 (2021). sourceExperimental — accuracy not yet measured
The Results section, “Neutralization of B.1.351 by vaccinee serum” (page unavailable), reports that serum from Pfizer-BioNTech vaccine recipients had a 7.6-fold lower geometric mean neutralization titer against B.1.351 than against Victoria. It does not report that 45% of mRNA-vaccine samples had a 3- to 10-fold reduction or that 30% had a greater-than-10-fold reduction. (LLM, conf=0.88)
- Partly supportedcites [117] Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021). sourceExperimental — accuracy not yet measured
The Results report reduced neutralization of the Beta (B.1.351) variant by sera from BNT162b2 mRNA-vaccine recipients: a 10-fold reduction in geometric mean activity in one assay and a 6- to 9-fold reduction in another. They do not report the claimed distribution of samples—45% with 3- to 10-fold reductions and 30% with reductions greater than 10-fold—or results from more than one mRNA vaccine. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“By contrast, among plasma samples obtained from recipients of the AZD1222 vaccine, higher proportions displayed reduced neutralizing activity against this variant 100,209,214 .”
What the sources say
- Partly supportedcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). sourceExperimental — accuracy not yet measured
The Results section, “Protection from B.1.617.1 and B.1.617.2 by vaccine serum” (page unavailable), reports that neutralization titers in serum from Oxford-AstraZeneca (AZD1222) recipients were 4.3-fold lower against B.1.617.2 (Delta) than against the Victoria strain. That supports reduced neutralizing activity, but the passage reports a reduction in the group's geometric mean titer, not a higher proportion of individual samples showing reduced activity. (LLM, conf=0.83)
- Partly supportedcites [209] Wall, E. C. et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet 397, 2331–2333 (2021). sourceExperimental — accuracy not yet measured
The main text (page not given; appendix p. 2 cited) reports that a higher proportion of samples from BNT162b2 recipients had low neutralising titres against B.1.617.2 (Delta) than against wild-type virus. It does not report this result for AZD1222 recipients; searches for AZD1222 and ChAdOx1 found no such analysis in our copy. (LLM, conf=0.86)
- Partly supportedcites [214] Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021). sourceExperimental — accuracy not yet measured
In “Sensitivity of Delta to sera from vaccinated individuals,” the paper reports that after one AstraZeneca (AZD1222) dose, only 9% of recipients’ sera neutralized Delta, compared with 74% for D614G and 61% for Alpha. The claim omits the dose qualification: four weeks after a second dose, sera from 95–100% of AstraZeneca recipients neutralized all four strains. The paper tested sera, rather than describing the samples as plasma. (LLM, conf=0.86)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The past several months have witnessed the emergence of four SArS-cov-2 variants of concern (Alpha, beta, Gamma and Delta)”
- Also stated in: § SARS-CoV-2 evolution · plain
“The four variants of concern, the Alpha variant (originally identified in the UK), the Beta variant (originally identified in South Africa), the Gamma variant (originally identified in Brazil) and the Delta variant (originally identified in India)”
What the sources say
- Not checked yetcites [27] Rambaut, A. et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. Virological https://virological.org/t/563 (2020).
- Not checked yetcites [16] Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021). This molecular epidemiological study charts the spread of the beta variant in South Africa and shows that it resulted from selective evolutionary forces. source
- Not checked yetcites [19] Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021). This paper presents an analysis showing that the Gamma variant is about twofold more transmissible than previous variants in Manaus, Brazil, and that it poses an increased risk of reinfection compared with previous variants. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § SARS-CoV-2 evolution · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The increasing number of SArS-cov-2 variants share a repertoire of mutations that is enabling the virus to spread despite rising population immunity while maintaining or increasing its replication fitness.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
In the paper
“In a post-hoc analysis of a NVX-CoV2373 clinical trial, vaccine efficacy was 86.3% against Alpha variants compared with 96.4% against non-Alpha variants 212 (TABLe 2).”
What the sources say
- Not checked yetcites [212] Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2107659 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“By the second quarter of 2021, the Alpha variant accounted for the majority of infections in the USA and many European countries 23,196 .”
What the sources say
- Not checked yetcites [23] Hodcroft, E. CoVariants: SARS-CoV-2 mutations and variants of interest (NextStrain). CoVariants https://covariants.org/ (2021).
- Not checked yetcites [196] Mullen, J. L. et al. Outbreak.info https://outbreak.info/citation (2020).
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“It was also associated with threefold to eightfold higher upper-airway levels [199][200][201]”
What the sources say
- Not checked yetcites [199] Golubchik, T. et al. Early analysis of a potential link between viral load and the N501Y mutation in the SARS-COV-2 spike protein. Preprint at bioRxiv https://doi.org/10.1101/2021.01.12.20249080 (2021). source
- Not checked yetcites [200] Kidd, M. et al. S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR. J. Infect. Dis. 223, 1666–1670 (2021). source
- Not checked yetcites [201] Borges, V. et al. Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) data, Portugal, week 49 2020 to week 3 2021. Eur. Surveill. 26, 2100131 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“and an estimated 50% increased mortality 194,195,202 .”
What the sources say
- Not checked yetcites [194] Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593, 270–274 (2021). source
- Not checked yetcites [195] Challen, R. et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 372, n579 (2021). source
- Not checked yetcites [202] Grint, D. J. et al. Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Eur. Surveill. 26, 2100256 (2021). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“The Beta variant was estimated to be 50% more transmissible than the lineages that preceded it 16 .”
What the sources say
- Not checked yetcites [16] Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021). This molecular epidemiological study charts the spread of the beta variant in South Africa and shows that it resulted from selective evolutionary forces. source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 8
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant 99,104,221 .”
What the sources say
- Partly supportedcites [99] Faulkner, N. et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. Elife 10, e69317 (2021). sourceExperimental — accuracy not yet measured
The Results and Discussion report reduced neutralisation of B.1.351 (Beta) by B.1.1.7 (Alpha) sera, with a 7.7-fold change and a range of 3.4- to 17.9-fold. They do not report the claimed breakdown of 59% and 18%; the Materials and methods describe 29 patients with B.1.1.7 infection, not 34. (LLM, conf=0.88)
- Partly supportedcites [104] Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2348–2361 (2021). sourceExperimental — accuracy not yet measured
The Results section reports reduced neutralization of Beta (B.1.351), but the 34 convalescent samples were collected before Alpha (B.1.1.7) emerged. The paper reports a separate Alpha-infected group of 13 patients, not 34, and does not report the claimed 59% and 18% breakdown for that group. Page numbers are unavailable in our copy. (LLM, conf=0.86)
- Partly supportedcites [221] McCallum, M. et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science 373, 648–654 (2021). sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports reduced neutralization of the Beta variant (B.1.351) by convalescent plasma. But its nine donors were likely infected with Wuhan-1 or a related virus, not Alpha, and it does not report the claimed 34 samples or the 59% and 18% breakdowns. (LLM, conf=0.84)
plaindirectn = 34- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“By June 2021, the Gamma variant accounted for a high proportion of infections in several South American and Caribbean countries 196 and 10% of US infections 33 .”
What the sources say
- Not checked yetcites [196] Mullen, J. L. et al. Outbreak.info https://outbreak.info/citation (2020).
- Partly supportedcites [33] Bolze, A. et al. Rapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States. Preprint at medRxiv https://doi.org/10.1101/2021.06.20.21259195 (2021). sourceExperimental — accuracy not yet measured
The Results (page not available) report that Gamma reached 15% of sequenced US samples by May 28–June 3, 2021. This supports a substantial US presence around June, but not the cited figure of 10% of infections. The South American and Caribbean statement carries a different citation and is not assessed here. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the mRNA vaccines appear to often elicit memory B cells that undergo somatic hypermutation, which should broaden the response to viruses with variant spike proteins 239,240 .”
What the sources say
- Partly supportedcites [239] Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431 (2021). sourceExperimental — accuracy not yet measured
The Memory B cells section reports continued somatic hypermutation after infection, and the Discussion says mRNA vaccination enhances memory B-cell responses and likely protects vaccinated convalescent individuals against variants (page not specified). But the paper says vaccine-driven expansion of persistent memory clones does not accumulate large numbers of additional mutations. It does not establish that mRNA vaccines often elicit this mutation-driven broadening in people without prior infection. (LLM, conf=0.88)
- Partly supportedcites [240] Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature https://doi.org/10.1038/s41586-021-03738-2 (2021). sourceExperimental — accuracy not yet measured
The paper reports persistent germinal-centre responses after mRNA vaccination and finds that a small fraction of cross-reactive B-cell clones had higher somatic hypermutation, suggesting a pre-existing memory B-cell origin (Abstract; page not provided). It does not show that vaccination often elicits memory B cells that undergo new somatic hypermutation, or establish that this process broadens responses to variant SARS-CoV-2 spike proteins. (LLM, conf=0.85)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Of convalescent plasma samples, about 40% had 3-fold to 10-fold and 15% had >10-fold reduced neutralizing activity 100,122,234 .”
What the sources say
- Partly supportedcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). sourceExperimental — accuracy not yet measured
The Results section, ‘Neutralization of B.1.617.1 by convalescent serum’ (page unavailable), reports reduced neutralization of the Kappa variant in convalescent samples, including a 3.9-fold reduction in geometric mean titer for B.1.617.1-B. It does not report that about 40% of samples had 3- to 10-fold reductions or that 15% had reductions greater than 10-fold; a group mean cannot establish those sample-level proportions. (LLM, conf=0.84)
- Partly supportedcites [122] Edara, V. V. et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N. Engl. J. Med. 385, 664–666 (2021) sourceExperimental — accuracy not yet measured
The paper’s main text (page unavailable) reports reduced neutralizing activity against B.1.617.1 (Kappa) in convalescent serum, including a lower geometric mean titer than against WA1/2020. It does not report that about 40% of samples had a 3- to 10-fold reduction or that 15% had a greater-than-10-fold reduction. (LLM, conf=0.86)
- Partly supportedcites [234] Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 36, 109415 (2021). sourceExperimental — accuracy not yet measured
The Results section ('Diminished neutralization by plasma from COVID-19 convalescent patients'; page unavailable) reports reduced neutralization of B.1.617 by plasma from 15 patients, averaging about 2-fold. It does not report that about 40% of samples had 3- to 10-fold reductions or that 15% had reductions greater than 10-fold. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The Alpha variant is susceptible to neutralization by most neutralizing mAbs as well as by most plasma samples from previously infected persons 97,102,121,149,159,[203][204][205][206] (fIg.5).”
What the sources say
- Not checked yetcites [97] Chen, X. et al. Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab646 (2021). This paper presents a systematic review and meta-analysis of in vitro neutralization studies of SARS-CoV-2 variants by convalescent and vaccinee plasma. source
- Not checked yetcites [102] Supasa, P. et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell 184, 2201–2211 (2021). source
- Not checked yetcites [121] Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021). This paper presents a comprehensive analysis of the effects of Alpha and Beta variant mutations on antibody neutralization. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The fact that the Alpha variant is rarely associated with reduced susceptibility to convalescent plasma is consistent with it not being associated with an increased risk of reinfection 207 .”
What the sources say
- Not checked yetcites [207] Graham, M. S. et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health 6, e335–e345 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“associated with increased transmissibility, increased risk of reinfection and/or reduced vaccine efficacy”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Beta variant is associated with reduced susceptibility to many mAbs because E484K interferes with binding of several RBM class 1 and 2 mAbs and K417N interferes with the binding of several RBM class 1 mAbs 104,117,121,163,217 .”
What the sources say
- Not checked yetcites [104] Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2348–2361 (2021). source
- Not checked yetcites [117] Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021). source
- Not checked yetcites [121] Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021). This paper presents a comprehensive analysis of the effects of Alpha and Beta variant mutations on antibody neutralization. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“E484K has resulted in 3-fold to 10-fold reduced susceptibility to about 30% and >10-fold reduced susceptibility to about 10% of convalescent plasma samples”
What the sources say
- Not checked yetcites [121] Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021). This paper presents a comprehensive analysis of the effects of Alpha and Beta variant mutations on antibody neutralization. source
- Not checked yetcites [130] Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44–57.e9 (2021). source
- Not checked yetcites [160] Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488.e4 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Alpha variant also contains several non-spike mutations including nsp6:Δ106-108 and the nucleocapsid mutations D3L, R203K and G204R, which may increase transmission by antagonizing innate immunity 25,[185][186][187] .”
What the sources say
- Not checked yetcites [25] Martin, D. P. et al. The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape. Preprint at medRxiv https://doi.org/10.1101/2021.02.23.21252268 (2021). source
- Not checked yetcites [185] Thorne, L. G. et al. Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant. Preprint at bioRxiv https://doi.org/10.1101/2021.06.06.446826 (2021). This systems biology study shows that in contrast to earlier SARS-CoV-2 variants, the alpha variant may owe its increased transmissibility and virulence to its antagonism of cellular innate immunity. source
- Not checked yetcites [186] Jiang, H. et al. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell Mol. Immunol. 17, 998–1000 (2020). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“N501Y increases ACE2 affinity 128,146,147 and increases virus replication in human upper-airway cells and in the upper respiratory tracts of hamsters 127”
What the sources say
- Not checked yetcites [128] Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310.e20 (2020). source
- Not checked yetcites [146] Zhu, X. et al. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies. PLoS Biol. 19, e3001237 (2021).
- Not checked yetcites [127] Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. Preprint at bioRxiv https://doi.org/10.1101/2021.03.08.434499 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In the previously cited Qatar cohort study, the efficacy of BNT162b against the Beta variant was estimated to be 72%, which was 15% lower than that for the Alpha variant 211 .”
What the sources say
- Not checked yetcites [211] Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N. Engl. J. Med. 385, 187-189 (2021). source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Even though E484Q is more likely than T478K to evade antibody neutralization 48,100,165 , only the Delta variant has demonstrated increased transmissibility, spreading to 54 countries and rapidly replacing the Alpha variant in the UK 32,35 and the USA 33 .”
What the sources say
- Not checked yetcites [48] Weisblum, Y. et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020). source
- Not checked yetcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). source
- Not checked yetcites [165] Ferreira, I. et al. SARS-CoV-2 B.1.617 mutations L452 and E484Q are not synergistic for antibody evasion. J. Infect. Dis. https://doi.org/10.1093/infdis/jiab368 (2021). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It also contains five NTD mutations, of which L18F has been shown to interfere with the binding of NTD-targeting neutralizing antibodies 51 .”
What the sources say
- Not checked yetcites [51] McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332–2347.e16 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“It was estimated to result in virus levels 3-4 times higher than earlier variants and to be responsible for an estimated 1.1-fold to 1.8-fold higher mortality 19 .”
What the sources say
- Not checked yetcites [19] Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021). This paper presents an analysis showing that the Gamma variant is about twofold more transmissible than previous variants in Manaus, Brazil, and that it poses an increased risk of reinfection compared with previous variants. source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Of the five FDA EUA-approved mAbs, bamlanivimab, etesevimab and casirivimab are largely inactive against B.1.351whereas imdevimab and sotrovimab, which bind to the RBD core, retain neutralizing activity 104,109,117,175,204 (TABLe 1).”
What the sources say
- Not checked yetcites [104] Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell 184, 2348–2361 (2021). source
- Not checked yetcites [109] Copin, R. et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 184, 3949–3961 (2021). source
- Not checked yetcites [117] Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“As the Gamma variant was associated with a surge of infections in a region of Brazil estimated to have achieved a high infection rate, it is suspected of being able to infect and cause illness in persons previously infected with other variants 19,29,30 .”
What the sources say
- Not checked yetcites [19] Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021). This paper presents an analysis showing that the Gamma variant is about twofold more transmissible than previous variants in Manaus, Brazil, and that it poses an increased risk of reinfection compared with previous variants. source
- Not checked yetcites [29] Buss, L. F. et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 371, 288–292 (2021). source
- Not checked yetcites [30] Sabino, E. C. et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet 397, 452–455 (2021). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Of convalescent plasma samples, about 40% display 3-fold to 10-fold and 10% display >10-fold reduced Iota variant neutralizing activity 166,235 .”
What the sources say
- Not checked yetcites [166] Zhang, L. et al. Comparison of 10 emerging SARS-CoV-2 variants: infectivity, animal tropism, and antibody neutralization. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-492659/v1 (2021). source
- Not checked yetcites [235] Zhou, H. et al. B.1.526 SARS-CoV-2 variants identified in new york city are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. mBio https://doi.org/10.1128/mBio.01386-21 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although SARS-CoV-2 variants differ in their transmission rates, disease severity and risk of reinfection, there is no evidence that they are differentially affected by non-pharmaceutical public health measures such as social distancing and the use of personal protective equipment, or that they will respond differently to most antiviral therapies.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The Zeta variant was common in Brazil in late 2020 and early 2021 (ref. 157 ), but appears to be decreasing in prevalence.”
What the sources say
- Not checked yetcites [157] Ferrareze, P. A. G. et al. E484K as an innovative phylogenetic event for viral evolution: genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. Infect. Genet. Evol. 93, 104941 (2021). source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The two most recently approved mAb preparations, casirivimab/imdevimab and sotrovimab, retain activity against all VOCs and VOIs, in part because imdevimab and sotrovimab target the RBD core whereas the most prevalent immune escape mutations are in the RBD RBM.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The Theta variant was first reported in March 2021 in the Philippines.It contains 13 lineage-defining mutations including N501Y, E484K, P681H and the NTD deletion at positions 141-143 (refs 155,156 ).”
What the sources say
- Not checked yetcites [155] Bascos, N. A. D., Mirano-Bascos, D. & Saloma, C. P. Structural analysis of spike protein mutations in an emergent SARS-CoV-2 variant from the Philippines. Preprint at bioRxiv https://doi.org/10.1101/2021.03.06.434059 (2021). source
- Not checked yetcites [156] Tablizo, F. A. et al. Genome sequencing and analysis of an emergent SARS-CoV-2 variant characterized by multiple spike protein mutations detected from the Central Visayas Region of the Philippines. Preprint at bioRxiv https://doi.org/10.1101/2021.03.03.21252812 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Of plasma samples from recipients of an mRNA vaccine, approximately 55% had 3-fold to 10-fold and 5% had >10-fold reduced neutralizing activity 100,118,122,234 .”
What the sources say
- Not checked yetcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). source
- Not checked yetcites [118] Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273–275 (2021). source
- Not checked yetcites [122] Edara, V. V. et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N. Engl. J. Med. 385, 664–666 (2021) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The Iota variant was first identified in New York state.In June 2021, it had a prevalence of 5-10% in the USA but remained rare outside the USA 154 .”
What the sources say
- Not checked yetcites [154] Annavajhala, M. K. et al. A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. Preprint at bioRxiv https://doi.org/10.1101/2021.02.23.21252259 (2021). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Beta and Gamma variants are each associated with increased transmissibility because of their ability to evade humoral immunity and cause reinfections.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“AY.1 and AY.2 are recently reported sub-lineages of the Delta variant that have developed additional mutations including the RBD mutation K417N (ref. 196 ).”
What the sources say
- Not checked yetcites [196] Mullen, J. L. et al. Outbreak.info https://outbreak.info/citation (2020).
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“It is highly prevalent in several South American countries and is associated with reduced susceptibility to the locally used CoronaVac vaccine 238 .”
What the sources say
- Not checked yetcites [238] Acevedo, M. L. et al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. Preprint at medRxiv https://doi.org/10.1101/2021.06.28.21259673 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In case-control studies from the UK, the BNT162b vaccine was approximately 85% effective for the Delta variant whereas the AZD1222 vaccine was approximately 60% effective 232,233 .”
What the sources say
- Not checked yetcites [232] Bernal, J. L. et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. N. Engl. J. Med. 385, 585–594 (2021). source
- Not checked yetcites [233] Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397, 2461–2462 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“It was estimated to be about 20% more transmissible than co-circulating lineages and to be associated with twofold higher upper-airway virus levels 123,192 .”
What the sources say
- Not checked yetcites [123] Deng, X. et al. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184, 3426–3437.e8 (2021). source
- Not checked yetcites [192] Peng, J. et al. Estimation of secondary household attack rates for emergent spike L452R SARS-CoV-2 variants detected by genomic surveillance at a community-based testing site in San Francisco. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab283 (2021). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The levels of neutralizing mAbs elicited by the mRNA vaccines has been high and in most persons are likely to be maintained for many months above the levels required for protection against even the most resistant circulating variants 164,239,240 .”
What the sources say
- Not checked yetcites [164] Greaney, A. J. et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci. Transl Med. 13, eabi9915 (2021). source
- Not checked yetcites [239] Wang, Z. et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature 595, 426–431 (2021). source
- Not checked yetcites [240] Turner, J. S. et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature https://doi.org/10.1038/s41586-021-03738-2 (2021). source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The Eta variant is present at low levels in many countries, with Nigeria having the highest proportion of infections 236 .”
What the sources say
- Not checked yetcites [236] Ozer, E. A. et al. High prevalence of SARS-CoV-2 B.1.1.7 (UK variant) and the novel B.1.525 lineage in Oyo State, Nigeria. Preprint at medRxiv https://doi.org/10.1101/2021.04.09.21255206 (2021). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“It results in approximately 3-fold to 10-fold reduced susceptibility to 45% and >10-fold reduced susceptibility to 5% of convalescent plasma samples 100,118,214,215,231 (fIg.5).”
What the sources say
- Not checked yetcites [100] Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4336 (2021). source
- Not checked yetcites [118] Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273–275 (2021). source
- Not checked yetcites [214] Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Alpha and Delta variants are each associated with increased transmissibility and greater disease severity because of immune evasion, and potentially because of higher virus levels resulting from the antagonism of innate immunity.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
In the paper
“This paper presents a meta-analysis showing that the level of neutralizing antibodies elicited by a vaccine is strongly correlated with its efficacy.”
What the sources say
- Not checked yetcites Khoury, D. S. et al.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This post-hoc analysis of a clinical trial shows that the beta variant was frequently responsible for reinfections in South Africa.”
What the sources say
- Not checked yetcites Shinde, V. et al.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This study demonstrates the likely importance of SARS-CoV-2 neutralizing mAb Fc-effector functions in an animal model.”
What the sources say
- Not checked yetcites Schäfer, A. et al.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This post-hoc analysis of a clinical trial shows that AZD1222 appeared ineffective at preventing infection with the beta variant.”
What the sources say
- Not checked yetcites Madhi, S. A. et al.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This experimental study shows that the plasma from persons infected with the beta variant can usually neutralize pre-variant viruses.”
What the sources say
- Not checked yetcites Moyo-Gwete, T. et al.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This systems biology study shows that in contrast to earlier SARS-CoV-2 variants, the alpha variant may owe its increased transmissibility and virulence to its antagonism of cellular innate immunity.”
What the sources say
- Not checked yetcites Thorne, L. G. et al.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This paper demonstrates that a high proportion of neutralizing antibodies elicited by SARS-CoV-2 infection will bind poorly to epitopes containing the spike RBD mutation E484K.”
What the sources say
- Not checked yetcites Greaney, A. J. et al.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These VOCs exhibit increased transmissibility and/or immune evasion, traits that have been linked to mutations in the viral spike (S) protein”
From The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic (2022) · cites this paper as Tao et al., 2021
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Self-citation
Research works printed but not linked: 1
- Edara, V. V., Hudson, W. H., Xie, X., Ahmed, R. & Suthar, M. S. Neutralizing antibodies against SARS-CoV-2 variants after infection and vaccination. JAMA 325, 1896–1898 (2021). · DOI · Paper page
Cited by
Sorted by citations
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Markov, P. V., Ghafari, M., Beer, M., Lythgoe, K., Simmonds, P., Stilianakis, N. I., & Katzourakis, A. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00878-2 · Cited by 1,179
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889
“These VOCs exhibit increased transmissibility and/or immune evasion, traits that have been linked to mutations in the viral spike (S) protein (Harvey et al., 2021b; Tao et al., 2021).”
InfluentialCRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 824
Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution
Starr, T. N., Greaney, A. J., Hannon, W. W., Loes, A. N., Hauser, K., Dillen, J. R., Ferri, E., Farrell, A. G., Dadonaite, B., McCallum, M., et al. (2022) · Science · doi:10.1126/science.abo7896 · Cited by 298
“Main text The SARS-CoV-2 spike receptor-binding domain (RBD) has undergone rapid evolution since the virus’s emergence (1).”
BackgroundSaxena, S. K., Kumar, S., Ansari, S. M., Pawęska, J., Maurya, V. K., Tripathi, A., & Abdel-Moneim, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27524 · Cited by 269
“Asn679Lys is close to the furin cleavage site and contributes to its polybasic character, which may enhance spike cleavage and help transmission.(8,19) It is still unsure how well the Omicron variant can be transmitted from one person to another person.”
BackgroundKhandia, R., Singhal, S., Alqahtani, T., Kamal, M. A., El-Shall, N. A., Nainu, F., Desingu, P. A., & Dhama, K. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112816 · Cited by 308
ACE2 binding is an ancestral and evolvable trait of sarbecoviruses
Starr, T. N., Zepeda, S. K., Walls, A. C., Greaney, A. J., Alkhovsky, S. V., Veesler, D., & Bloom, J. D. (2022) · Nature · doi:10.1038/s41586-022-04464-z · Cited by 207
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir
Ullrich, S., Ekanayake, K. B., Otting, G., & Nitsche, C. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128629 · Cited by 197
Gu, H.-G., Krishnan, P., Ng, D. Y. M., Chang, L., Liu, G. Y. Z., Cheng, S. M. S., Hui, M., Fan, M. C. Y., Wan, J. H. L., Lau, L. H., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2802.212422 · Cited by 174
Petersen, E., Ntoumi, F., Hui, D. S. C., Abubakar, A., Kramer, L., Obiero, C., Tambyah, P., Blumberg, L., Yapi, R., Al-Abri, S., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.040 · Cited by 158
Gut microbiota: A new insight into lung diseases
Ma, P.-J., Wang, M., & Wang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113810 · Cited by 171
Cohen, C., Kleynhans, J., Gottberg, A. V., McMorrow, M. L., Wolter, N., Bhiman, J. N., Moyes, J., Plessis, M. D., Carrim, M., Buys, A., et al. (2021) · doi:10.1101/2021.07.20.21260855 · Cited by 153
“6,7 Studies to quantify the burden of asymptomatic infections, symptomatic fraction, reinfection frequency, duration of shedding, and household transmission of SARS-CoV-2 from asymptomatically infected individuals have mostly been conducted as part of outbreak investigations or in specific settings.”
The Beneficial Role of Probiotic Lactobacillus in Respiratory Diseases
Du, T., Lei, A., Zhang, N., & Zhu, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908010 · Cited by 156
Struelens, M. J., Ludden, C., Werner, G., Sintchenko, V., Jokelainen, P., & Ip, M. (2024) · Frontiers in Science · doi:10.3389/fsci.2024.1298248 · Cited by 162
Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity
Markov, P. V., Katzourakis, A., & Stilianakis, N. I. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00722-z · Cited by 149
COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment
Karoui, K. E., & Vriese, A. S. D. (2022) · Kidney International · doi:10.1016/j.kint.2022.01.022 · Cited by 150
“The Delta VOC has globally displaced the other VOCs, is highly transmissible, and has greater pathogenicity.(21) The more recently described B.”
BackgroundComparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA
Earnest, R., Uddin, R., Matluk, N. N., Renzette, N., Siddle, K., Loreth, C., Adams, G., Tomkins-Tinch, C., Petrone, M. E., Rothman, J. E., et al. (2021) · medRxiv · doi:10.1101/2021.10.06.21264641 · Cited by 125
“Delta, containing the spike L452R and P681Hmutations (in the receptorbindingdomainandnear the furin cleavage site, respectively) that may affect antibody recognition, was first recognized in India in early 2021 and displaced Alpha as the dominant variant bymid-2021.(5) This shift led to a significant resurgence in COV…”
Drivers of adaptive evolution during chronic SARS-CoV-2 infections
Harari, S., Tahor, M., Rutsinsky, N., Meijer, S. E., Miller, D., Henig, O., Halutz, O., Levytskyi, K., Ben‐Ami, R., Adler, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01882-4 · Cited by 139
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
Reynolds, C. J., Gibbons, J. M., Pade, C., Lin, K., Sandoval, D. M., Pieper, F. P., Butler, D. K., Liu, S., Otter, A. D., Joy, G., et al. (2022) · Science · doi:10.1126/science.abm0811 · Cited by 130
Tzou, P. L., Tao, K., Pond, S. L. K., & Shafer, R. W. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261045 · Cited by 126
“Centers for Disease Control and Prevention (reviewed in [1]).”
BackgroundSelf-citationDhawan, M. K., Saied, A. A., Mitra, S., Alhumaydhi, F. A., Emran, T. B., & Wilairatana, P. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113522 · Cited by 130
RetractedEmergence of immune escape at dominant SARS-CoV-2 killer T cell epitope
Dolton, G. M., Rius, C., Hasan, M. S., Wall, A., Szomolay, B., Behiry, E. M., Whalley, T., Southgate, J., Fuller, A., Morin, T., et al. (2022) · Cell · doi:10.1016/j.cell.2022.07.002 · Cited by 100
“SARS-CoV-2 variants have been rapidly emerging throughout the current pandemic with mutants that enhance transmissibility, evade host immunity, or increase disease severity being of particular concern (Tao et al., 2021).”
Schubert, M., Bertoglio, F., Steinke, S., Heine, P. A., Ynga-Durand, M. A., Maaß, H., Sammartino, J. C., Cassaniti, I., Zuo, F., Du, L., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02312-5 · Cited by 92
“The K417N mutation is a key mutation also in the Beta variant, the T478K mutation instead in the Delta variant, and N501Y in the Alpha, Beta, and Gamma variants [50].”
BackgroundLee, J. T., Yang, Q., Gribenko, A. V., Perrin, B. S., Zhu, Y., Cardin, R. D., Liberator, P., Anderson, A. S., & Li, H. (2022) · mBio · doi:10.1128/mbio.00869-22 · Cited by 106
“Characterization of emergent variants has centered on the number and location of mutations in the S protein trimer (8).”
Pastorio, C., Zech, F., Noettger, S., Jung, C., Jacob, T., Sanderson, T., Sparrer, K. M. J., & Kirchhoff, F. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.006 · Cited by 95
“Their increased transmissibility, efficient immune evasion and altered pathogenicity are mainly determined by the viral spike (S) protein (Harvey et al., 2021; Jung et al., 2022; Tao et al., 2021).”
Song, J., Cha, B., Moon, J., Jang, H., Kim, S., Jang, J., Yong, D., Kwon, H., Lee, I., Lim, E., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04840 · Cited by 104
Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta
Ulrich, L., Halwe, N. J., Taddeo, A., Ebert, N., Schön, J., Devisme, C., Trüeb, B. S., Hoffmann, B., Wider, M., Fan, X., et al. (2021) · Nature · doi:10.1038/s41586-021-04342-0 · Cited by 98
Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA
Earnest, R., Uddin, R., Matluk, N. N., Renzette, N., Turbett, S. E., Siddle, K. J., Loreth, C., Adams, G. C., Tomkins-Tinch, C. H., Petrone, M. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100583 · Cited by 199
“Delta, containing the spike L452R and P681Hmutations (in the receptorbindingdomainandnear the furin cleavage site, respectively) that may affect antibody recognition, was first recognized in India in early 2021 and displaced Alpha as the dominant variant bymid-2021.(5) This shift led to a significant resurgence in COV…”
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern
Akkız, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.849217 · Cited by 102
“In addition to two mutations, delta also contains a unique mutation, T478K (threonine T replaced by lysine K) (14).”
BackgroundInfluentialSARS-CoV-2 and innate immunity: the good, the bad, and the “goldilocks”
Sievers, B. L., Cheng, M. T. K., Csiba, K., Meng, B., & Gupta, R. K. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01104-y · Cited by 91
Self-citationRaglow, Z., Surie, D., Chappell, J. D., Zhu, Y., Martin, E. T., Kwon, J. H., Frosch, A. E. P., Mohamed, A., Gilbert, J., Bendall, E. E., et al. (2024) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00336-1 · Cited by 90
Immunity to SARS-CoV-2 up to 15 months after infection
Marcotte, H., Piralla, A., Zuo, F., Du, L., Cassaniti, I., Wan, H., Kumagai‐Braesch, M., Andréll, J., Percivalle, E., Sammartino, J. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103743 · Cited by 83
Plasticity in structure and assembly of SARS-CoV-2 nucleocapsid protein
Zhao, H., Nguyen, A., Wu, D., Li, Y., Hassan, S. A., Chen, J., Shroff, H., Piszczek, G., & Schuck, P. (2022) · doi:10.1101/2022.02.08.479556 · Cited by 75
“2 (Delta) that in 2021 has rapidly outperformed all previous variants (30) (Fig.”
BackgroundA variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Pang, W., Lu, Y., Zhao, Y., Shen, F., Fan, C., Wang, Q., He, W.-Q., He, X.-Y., Li, Z., Chen, T., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00746-3 · Cited by 76
RNA G-quadruplex in TMPRSS2 reduces SARS-CoV-2 infection
Liu, G., Du, W., Sang, X., Tong, Q., Wang, Y., Chen, G., Yuan, Y., Jiang, L., Cheng, W., Liu, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29135-5 · Cited by 98
Interferon resistance of emerging SARS-CoV-2 variants
Guo, K., Barrett, B. S., Morrison, J. H., Mickens, K. L., Vladar, E. K., Hasenkrug, K. J., Poeschla, E. M., & Santiago, M. L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203760119 · Cited by 141
Masood, K. I., Yameen, M., Ashraf, J., Shahid, S., Mahmood, S. F., Nasir, A., Nasir, N., Jamil, B., Ghanchi, N. K., Khanum, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02489-4 · Cited by 94
Aptamers targeting SARS-COV-2: a promising tool to fight against COVID-19
Zhang, Y., Juhas, M., & Kwok, C.-K. (2022) · Trends in Biotechnology · doi:10.1016/j.tibtech.2022.07.012 · Cited by 70
“This is particularly the case for S protein which forms a trimeric structure on the viral envelope [3,54].”
Li, H., Gong, H., Wong, T. H., Zhou, J., Wang, Y., Lin, L., Dou, Y., Jia, H., Huang, X., Gao, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43189-z · Cited by 67
Giovanetti, M., Fonseca, V., Wilkinson, E., Tegally, H., San, J. E., Althaus, C. L., Xavier, J., Slavov, S. N., Viala, V. L., Lima, A. R. J., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac024 · Cited by 75
Updated picture of SARS-CoV-2 variants and mutations
Lippi, G., Mattiuzzi, C., & Henry, B. M. (2021) · Diagnosis · doi:10.1515/dx-2021-0149 · Cited by 74
A Global Picture: Therapeutic Perspectives for COVID-19
Chavda, V. P., Kapadia, C., Soni, S., Prajapati, R., Chauhan, S. C., Yallapu, M. M., & Apostolopoulos, V. (2022) · Immunotherapy · doi:10.2217/imt-2021-0168 · Cited by 88
“Any alteration between amino acid remnants 319–541 – particularly between 438 and 506 – might have a significant impact on the virus affinity to infections, transmissibility, severity and immunity-evading abilities [24].”
BackgroundRecent review of COVID-19 management: diagnosis, treatment and vaccination
Chavda, V. P., Vuppu, S., Mishra, T., Kamaraj, S., Patel, A., Sharma, N., & Chen, Z. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00425-5 · Cited by 73
Zhang, B., Shuai, H., Gong, H., Hu, J., Yan, B., Yuen, T. T., Hu, Y., Yoon, C., Wang, X., Hou, Y., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157393 · Cited by 67
Structures of Omicron spike complexes and implications for neutralizing antibody development
Guo, H., Gao, Y., Li, T., Li, T., Lu, Y., Zheng, L., Liu, Y., Yang, T., Luo, F., Song, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110770 · Cited by 61
“The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants associated with increased virulence or infectivity that occurred during the late months of 2020 has caused massive outbreaks in different regions (Tao et al., 2021; Wu et al., 2020; Zhou et al., 2020).”
BackgroundChest CT Findings in Hospitalized Patients with SARS-CoV-2: Delta versus Omicron Variants
Yoon, S. H., Lee, J. H., & Kim, B.-N. (2022) · Radiology · doi:10.1148/radiol.220676 · Cited by 59
Tegally, H., Wilkinson, E., Tsui, J. L.-H., Moir, M., Martin, D., Brito, A. F., Giovanetti, M., Khan, K., Huber, C., Bogoch, I. I., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.001 · Cited by 77
“Along with some less successful novel lineages (termed variants of interest or VOIs), these VOCs were characterized by a combination of increased intrinsic transmissibility, sometimes enhanced immune evasion capabilities, and increased pathogenicity.(4) Each of the VOCs was associated initially with increasing SARS-Co…”
BackgroundRecent advances in point of care testing for COVID-19 detection
Fernandes, R. S., Silva, J. D. O., Gomes, K. B., Azevedo, R. B., Townsend, D. M., Sabino, A. D. P., & de Barros, A. L. B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113538 · Cited by 73
“5 copies/μL input, and it is 100% consistent with rRT-PCR [25].”
SARS-CoV-2 variants – Evolution, spike protein, and vaccines
Chen, K.-W. K., Huang, D. T., & Huang, L. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.04.006 · Cited by 63
“[21] Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al.”
InfluentialFitness, growth and transmissibility of SARS-CoV-2 genetic variants
Volz, E. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00610-z · Cited by 51
Cai, S., Zhang, C., Zhuang, Z., Zhang, S., Ma, L., Yang, S., Zhou, T., Wang, Z., Xie, W., Jin, S., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01420-9 · Cited by 62
“Different SARS-CoV-2 variants triggered different immune response.(4) To further depict the relationship between LLPS ability and the function of N protein, we constructed and purified recombinant-N protein from Alpha (B.”
BackgroundMethodAn atlas of continuous adaptive evolution in endemic human viruses
Kistler, K. E., & Bedford, T. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.09.012 · Cited by 65
“Thus, the early stages of a pandemic are often marked by high rates of adaptive evolution, as was noted for the 2009 H1N1 pandemic 1,2,3 , and during the emergence and spread of ‘variant’ viruses during the SARS-CoV-2 pandemic in late 2020 and early 2021 4 .”
Ortega, J. T., Jastrzębska, B., & Rangel, H. R. (2021) · Pathogens · doi:10.3390/pathogens11010045 · Cited by 60
“These mutations, depending on the location and the type, can produce changes in the viral fitness and/or pathogenicity [2,3].”
BackgroundUnlocking capacities of genomics for the COVID-19 response and future pandemics
Knyazev, S., Chhugani, K., Sarwal, V., Ayyala, R., Singh, H., Karthikeyan, S., Deshpande, D., Baykal, P. I., Comarova, Z., Lu, A., et al. (2022) · Nature Methods · doi:10.1038/s41592-022-01444-z · Cited by 61
Du, W., Hurdiss, D. L., Drabek, D., Mykytyn, A. Z., Kaiser, F. K., González-Hernández, M., Muñoz‐Santos, D., Lamers, M. M., van Haperen, R., Li, W., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp9312 · Cited by 56
Rando, H. M., MacLean, A. L., Lee, A. J., Lordan, R., Ray, S., Bansal, V., Skelly, A. N., Sell, E., Dziak, J. J., Shinholster, L., et al. (2021) · mSystems · doi:10.1128/msystems.00095-21 · Cited by 42
“Several VOCs have also been identified and designated through molecular surveillance efforts (223).”
Toelzer, C., Gupta, K., Yadav, S. K. N., Hodgson, L. R., Williamson, M. K., Buzas, D., Borucu, U., Powers, K. T., Stenner, R., Vasileiou, K., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9179 · Cited by 49
“8, eadc9179 (2022) 23 November 2022 5 of 12 S C I E N C E A D VA N C E S | R E S E A R C H A R T I C L E”
InfluentialCirculating microRNAs as emerging regulators of COVID-19
Liang, Y., Fang, D., Gao, X., Deng, X., Chen, N., Wu, J., Min De, Z. E. N. G., & Luo, M. (2022) · Theranostics · doi:10.7150/thno.78164 · Cited by 54
“Currently, SARS-CoV-2 continues to mutate and COVID-19 continues to spread globally [136].”
BackgroundSARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
van Doremalen, N., Singh, M., Saturday, T. A., Yinda, C. K., Pérez-Pérez, L., Bohler, F., Weishampel, Z. A., Lewis, M. C., Schulz, J. E., Williamson, B. N., et al. (2022) · Science Advances · doi:10.1126/sciadv.ade1860 · Cited by 47
“A. Bolze, S. Luo, S. White, E. T. Cirulli, D. Wyman, A. D. Rossi, H. Machado, T. Cassens, S. Jacobs, K. M. Schiabor Barrett, F. Tanudjaja, K. Tsan, J. Nguyen, J. M. Ramirez III, E. Sandoval, X. Wang, D. Wong, D. Becker, M. Laurent, J. T. Lu, M. Isaksson, N. L. Washington, W. Lee, SARS-CoV-2 variant Delta rapidly displ…”
BackgroundInfluentialOMICRON: Virology, immunopathogenesis, and laboratory diagnosis
Bazargan, M., Elahi, R., & Esmaeilzadeh, A. (2022) · The Journal of Gene Medicine · doi:10.1002/jgm.3435 · Cited by 53
Saxena, S. K., Kumar, S., Ansari, S. M., Pawęska, J., Maurya, V. K., Tripathi, A., & Abdel-Moneim, A. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27611 · Cited by 46
“The frequency of the crucial mutations was compared with the other prevalent VOCs.17”
BackgroundInfluentialBroad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges
Wang, Z.-L., & Yang, L.-Y. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27517 · Cited by 45
“There has been a gradual decline in safety and efficacy with increased time since vaccines were administered.(12,13)”
BackgroundChoi, J. H., Jun, M. S., Jeon, J. Y., Kim, H.-S., Kim, Y. K., Jeon, C. H., Choi, S. H., Kim, D. S., Han, M., & Oh, J. W. (2023) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0118 · Cited by 44
“[7] Several factors have contributed to the emergence of new variants, including the high global prevalence of the virus, the large number of infected individuals, and the limited access to vaccines in many parts of the world.”
Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection
Hariharan, V. N., Shin, M., Chang, C., O’Reilly, D., Biscans, A., Yamada, K., Guo, Z., Somasundaran, M., Tang, Q., Monopoli, K. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219523120 · Cited by 49
Genetic diversity of SARS-CoV-2 infections in Ghana from 2020-2021
Morang’a, C. M., Ngoi, J. M., Gyamfi, J., Amuzu, D. S. Y., Nuertey, B. D., Soglo, P. M., Appiah, V., Asante, I. A., Owusu-Oduro, P., Armoo, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30219-5 · Cited by 48
Vaccination and COVID-19 Dynamics in Dialysis Patients
Karoui, K. E., Hourmant, M., Ayav, C., Glowacki, F., Couchoud, C., Lapidus, N., & on behalf of the REIN Registry (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10300721 · Cited by 48
“Lastly, our data did not include important virologic factors such as the spread of variant of concern types in both populations (23).”
BackgroundAlhamlan, F. S., & Al-Qahtani, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031263 · Cited by 46
“Immune evasion properties of E484K and K417T mutations led to reinfections and reduced vaccine effectiveness, particularly for non-mRNA vaccines [26].”
Girón-Guzmán, I., Cuevas-Ferrando, E., Barranquero, R., Díaz-Reolid, A., Puchades-Colera, P., Falcó, I., Pérez-Cataluña, A., & Sánchez, G. (2024) · Water Research · doi:10.1016/j.watres.2024.121463 · Cited by 43
Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review
Nanishi, E., Levy, O., & Ozonoff, A. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2045857 · Cited by 46
“Several SARS-CoV-2 variants harboring mutations are associated with decreased mRNA VE against infection and/or severe COVID-19 due to increased transmissibility and immune escape from vaccine induced immune memory.(23) Each variant differs with respect to its clinical significance.”
BackgroundMechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy
Zhao, Y., Gan, L., Ke, D., Chen, Q., & Fu, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04553-1 · Cited by 45
Ma, H., Zhang, X., Zheng, P., Dube, P. H., Zeng, W., Chen, S., Cheng, Q., Yang, Y., Wu, Y., Zhou, J., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00700-3 · Cited by 42
Yamamoto, M., Gohda, J., Kobayashi, A., Tomita, K., Hirayama, Y., Koshikawa, N., Seiki, M., Semba, K., Akiyama, T., Kawaguchi, Y., et al. (2022) · mBio · doi:10.1128/mbio.00519-22 · Cited by 47
Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease
Samuel, C. E. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104960 · Cited by 50
“The virus spread quickly, and its fitness continued to evolve (9-11).”
An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia
Lee, J. H., Koh, J., Jeon, Y. K., Goo, J. M., & Yoon, S. H. (2023) · Radiology · doi:10.1148/radiol.222600 · Cited by 40
“As a result of genetic variations of SARS-CoV-2 during viral replication (8,9), several variants of SARS-CoV-2 have been reported worldwide throughout the pandemic with increased transmissibility and evasiveness of treatments and vaccines (eg, the Delta and Omicron variants).”
BackgroundEmergence of SARS-CoV-2 Variants in the World: How Could This Happen?
Parra-Lucares, A., Segura, P., Rojas, V. A., Pumarino, C., Saint-Pierre, G., & Toro, L. (2022) · Life · doi:10.3390/life12020194 · Cited by 49
Lippi, G., Adeli, K., & Plebani, M. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-1287 · Cited by 43
“This is not really surprising, since coronaviruses tend to mutate over time, though to lower extent compared to Influenza virus, for example [14].”
BackgroundChakraborty, C., Bhattacharya, M., & Sharma, A. R. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.11.006 · Cited by 45
Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants
Moriyama, M., Lucas, C. G. D. O., Monteiro, V. S., Initiative, Y. S.-C.-2. G. S., Iwasaki, A., Chen, N., Breban, M. I., Hahn, A. M., Pham, K., Koch, T. R., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221652120 · Cited by 56
“The enhanced immune evasion by VOCs has been well documented for escape from neutralizing antibodies (6–8) and from innate immune responses (4, 5).”
BackgroundInfluentialRouet, R., Henry, J. Y., Johansen, M. D., Sobti, M., Balachandran, H., Langley, D. B., Walker, G. J., Lenthall, H., Jackson, J., Ubiparipovic, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36295-5 · Cited by 41
Molecular Virology of SARS-CoV-2 and Related Coronaviruses
Kung, Y.-A., Lee, K.-M., Chiang, H.-J., Huang, S., Wu, C.-J., & Shih, S. (2022) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00026-21 · Cited by 50
“This mechanism facilitates the replicase jump from the 39 region to the 59 end of the template and generates several discontinuous (2)sgRNAs with identical terminal sequences antisense to the leader sequence.”
BackgroundMethodInfluentialForecasting COVID-19 cases using time series modeling and association rule mining
Somyanonthanakul, R., Warin, K., Amasiri, W., Mairiang, K., Mingmalairak, C., Panichkitkosolkul, W., Silanun, K., Theeramunkong, T., Nitikraipot, S., & Suebnukarn, S. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01755-x · Cited by 37
“Since the first outbreak, COVID-19 has mutated into many variants including the alpha, beta and delta SARS-COV-2 variants, which have been associated with new waves of infection [3].”
BackgroundEmergence of SARS-CoV-2 New Variants and Their Clinical Significance
Singh, H., Dahiya, N., Yadav, M., & Sehrawat, N. (2022) · The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · doi:10.1155/2022/7336309 · Cited by 37
Khan, A., Randhawa, A. W., Balouch, A. R., Mukhtar, N., Sayaf, A. M., Suleman, M., Khan, T., Ali, S., Ali, S. S., Wang, Y., et al. (2022) · RSC Advances · doi:10.1039/d2ra00277a · Cited by 40
Rosales, R., McGovern, B., Rodríguez, M., Rai, D., Cardin, R., Anderson, A. S., Sordillo, E., van Bakel, H., Simon, V., García-Sastre, A., et al. (2022) · bioRxiv · doi:10.1101/2022.01.17.476685 · Cited by 36
New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic
Carvajal, J. J., García-Castillo, V., Cuellar, S. V., Campillay-Véliz, C. P., Salazar‐Ardiles, C., Avellaneda, A. M., Muñoz, C. A., Retamal-Díaz, A. R., Bueno, S. M., González, P. A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1363572 · Cited by 42
Carbo, E., Mourik, K., Boers, S. A., Munnink, B. O., Nieuwenhuijse, D., Jonges, M., Welkers, M., Matamoros, S., Slooten, J. V. H. T., Kraakman, M., et al. (2023) · European Journal of Clinical Microbiology and Infectious Diseases · doi:10.1007/s10096-023-04590-0 · Cited by 35
Rapid detection of SARS-CoV-2: The gradual boom of lateral flow immunoassay
He, J., Zhu, S., Zhou, J., Jiang, W., Yin, L., Su, L., Zhang, X., Chen, Q., & Li, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1090281 · Cited by 44
Windsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 37
“INTRODUCTION The high global rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections leads to regular emergence of previously unidentified variants (1).”
Tetz, G. V., & Tetz, V. (2022) · Microorganisms · doi:10.3390/microorganisms10020280 · Cited by 54
Rai, D., Yurgelonis, I., McMonagle, P., Rothan, H., Hao, L., Gribenko, A. V., Titova, E., Kreiswirth, B. N., White, K., Zhu, Y.-A., et al. (2022) · bioRxiv · doi:10.1101/2022.01.17.476644 · Cited by 35
“Similar to other coronaviruses, SARS-CoV-2 encodes an RNA virus 3′→5′ exoribonuclease which reduces its mutation rate, but the genome of SARS-CoV-2 still accumulates mutations over time which could impact viral characteristics, such as transmissibility, virulence or escape from the immune system or therapeutics [4-6].”
ResultPathogenesis and Mechanisms of SARS-CoV-2 Infection in the Intestine, Liver, and Pancreas
Khreefa, Z., Barbier, M. T., Köksal, A. R., Love, G. L., & Valle, L. D. (2023) · Cells · doi:10.3390/cells12020262 · Cited by 41
“Spike protein mutations result in the emergence of new viral variants, which can be more contagious and potentially resistant to vaccines [9,10].”
BackgroundA comprehensive review on Covid-19 Omicron (B.1.1.529) variant
Manjunath, R., Gaonkar, S. L., Saleh, E. A. M., & Husain, K. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103372 · Cited by 42
SARS-CoV-2: phenotype, genotype, and characterization of different variants
Saberiyan, M., Karimi, E., Khademi, Z., Movahhed, P., Safi, A., & Ghahfarrokhi, A. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00352-6 · Cited by 56
“Beta variant lacks the 69–70/del mutation observed in other variants [35].”
BackgroundInfluentialFirst-generation oral antivirals against SARS-CoV-2
Sendi, P., Razonable, R. R., Nelson, S. B., Soriano, À., & Gandhi, R. T. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.04.015 · Cited by 34
“Evolution and constituent mutations of SARS-CoV-2 have hitherto mainly affected the genetic variability of the spike proteins, resulting in emergent SARS-CoV-2 variants and diminishment or loss of effect of antieSARS-CoV-2 monoclonal antibody therapies [2,43].”
BackgroundAntibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
Javanmardi, K., Segall-Shapiro, T. H., Chou, C., Boutz, D. R., Olsen, R. J., Xie, X., Xia, H., Shi, P., Johnson, C. D., Annapareddy, A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.07.016 · Cited by 39
“The continuous evolution and spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has produced variants of concern (VOCs) and variants of interest (VOIs) with enhanced immune evasion, transmissibility, and occasionally increased disease severity (Davies et al., 2021; Mlcochova et al., 2021; Saito et…”
Valanparambil, R. M., Carlisle, J. W., Linderman, S. L., Akhtar, A., Millett, R. L., Lai, L., Chang, A., McCook‐Veal, A. A., Switchenko, J. M., Nasti, T. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02986 · Cited by 48
“Numerous SARS-CoV-2 VOCs are currently evolving, which evade vaccine-induced antibody response even in vaccinated healthy individuals.(24) This leaves patients with cancer with immune dysfunction at a higher risk to contract severe SARS-CoV-2 infection.”
BackgroundInvestigating the evolutionary origins of the first three SARS-CoV-2 variants of concern
Ghafari, M., Liu, Q., Dhillon, A., Katzourakis, A., & Weissman, D. B. (2022) · Frontiers in Virology · doi:10.3389/fviro.2022.942555 · Cited by 35
“The table shows the amino acid changes across the SARS-CoV-2 genome that are shared between at least two of the three VOCs (7).”
Background
Metadata
- Authors
- Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W.
- Affiliations
- Stanford Medicine (US)
- University of Cambridge (GB)
- Swarthmore College (US)
- Corresponding author
- Shafer, Robert W.
- Venue
- Nature Reviews Genetics
- Published
- 2021-09-17
- Volume
- 22
- Issue
- 12
- Pages
- 757-773
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- PMC
- PMC8447121
- OpenAlex
- W3199849883
- Cited by
- 1,009
- References
- 281
- Citations by year
- 2026: 43 · 2025: 90 · 2024: 170 · 2023: 251 · 2022: 415 · 2021: 38
- FWCI
- 25.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Nature Reviews Genetics (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Works - Scholarship, Research, & Creative Expression (Swarthmore College) (submittedVersion)
- Funders
- University of Washington
- National Institute of Allergy and Infectious Diseases (R24AI136618)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- SARS-CoV-2, COVID-19 variants of concern, spike protein mutations, Alpha variant, Beta variant, Gamma variant, Delta variant, virus transmission, reinfection risk, neutralizing antibodies, vaccine effectiveness, herd immunity, viral replication fitness
- MeSH terms
- COVID-19, SARS-CoV-2, Epitopes, Biological Evolution, Humans, Mutation, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
